楚天科技股份有限公司 公 司 章 程 二零二五年四月 | | | 第一章 总则 第一条 为维护楚天科技股份有限公司（以下简称"公司"）、股东、职 工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》） 和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司系在原长沙楚天科技有限公司基础上整体变更设立；在长沙市市场监督管 理局注册登记，取得营业执照，统一社会信用代码91430100743176293C。 第三条 公司于2013年12月30日经中国证券监督管理委员会核准，首次向 社会公众公开发行人民币普通股1824.9813万股，于2014年1月21日在深圳证券交易 所上市。 第四条 公司注册中文名称：楚天科技股份有限公司。 英文名称： TRUKING TECHNOLOGY LIMITED. 第五条 公司住所：宁乡市玉潭镇新康路 1 号，邮政编码：410600。 第六条 公司注册资本为人民币 59030.4736万元，实收资本数额为人民币 59030.4736 万元。 第七条 公司 ...

楚天科技股份有限公司 子公司管理制度 第一章 总 则 第一条 为优化楚天科技股份有限公司（简称"公司"）及其控股、全资子 公司（以下统称"子公司"）的管理机制，确保子公司规范运营，保障股东合法 权益，依据《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证 券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称 "《规范运作指引》"）以及《楚天科技股份有限公司章程》（以下简称"《公 司章程》"）等相关法律法规，并结合公司实际情况，特制定本制度。 第二条 本制度部分用语含义为： （一）"子公司"，是指公司根据总体战略规划、产业结构调整及业务发展 需要而依法设立的，具有独立法人资格，公司依据章程或协议有权决定其财务和 经营决策，据以从该企业的经营活动中获取利益的子公司。其设立形式包括： 1、全资子公司； 2、公司与其他公司或自然人共同出资设立的，公司控股 50%以上（不含 50%） 或派出董事占其董事会决大多数席位（控制其董事会）的控股子公司或通过协议、 其他安排能实现控制的子公司。 （二）"子公司管理"，是指公司作 ...

楚天科技股份有限公司 2024年度独立董事述职报告 （张早平） 各位股东及股东代表： 本人张早平，担任楚天科技股份有限公司（以下简称"楚天科技"或"公 司"）第五届董事会的独立董事。在履职期间，我严格遵循《中华人民共和国公 司法》、《中华人民共和国证券法》、《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关 法律、法规及规范性文件，以及《公司章程》、《独立董事工作细则》等内部规 定，秉持诚实、勤勉、独立的原则，认真履行职责。我积极参与各项会议，审慎 审议董事会各项议案，并对公司重大事项提出独立见解，充分发挥了独立董事及 专业委员会的职能，切实维护了全体股东，尤其是中小股东的合法权益。 现将本人2024年度履职情况总结如下： 一、基本情况 本人张早平，1965年12月出生，中国国籍，无境外永久居留权，博士，研究 员职称（2005年9月）。系湖南省十二届人大法制委委员，湖南省立法研究会副 会长，长沙市人民政府首批法制专家库专家，湖南省地方金融监督管理立法建设 主要参与者之一。曾在长沙市人事局军培中心、湖南华大电力科技开发公司任职。 现任长沙大地经济发展研究 ...

第一章 总 则 第一条 为规范楚天科技股份有限公司（以下简称"公司"）董事、 高级管理人员所持本公司股份及其变动的管理，进一步明确管理程序，确 保信息披露工作合规，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 2 号—创业板上市公司规范运作》等相关法律、法规、规范 性文件，以及《楚天科技股份有限公司章程》（以下简称"《公司章程》"） 的明确规定，特制定本制度。 楚天科技股份有限公司 董事、高级管理人员持股及变动管理制度 第二条 本制度适用于公司董事和高级管理人员所持本公司股份及其 变动的管理。 第三条 公司董事和高级管理人员所持股份，是指登记在其名下的所 有本公司股份及其衍生产品（包括但不限于可转换债券、股权激励计划所 发行的股票期权及股票增值权）等；董事和高级管理人员从事融资融券交 易的，还包括记载在其他信用账户内的本公司股份及其衍生产品，同时亦 包括任何股权激励计划所发行的股票期权及股票增值权。 第四条 公司董事和高级管理人员在买卖本公司股票及其衍生品种前， 应 ...

楚天科技股份有限公司 独立董事工作制度 第一章 总 则 1 会计专业人士应当具备丰富的会计专业知识和经验，并至少符合下列条件之一： 第一条 为进一步完善楚天科技股份有限公司（以下简称"公司"）的法人治 理结构，加强对董事会和经理层的约束与监督，提升公司决策的科学性与民主性， 维护公司及全体股东的利益，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》等相关法律、法规，以及《楚天科技股份有 限公司章程》（以下简称"《公司章程》"或"公司章程"）的规定，遵循《深圳 证券交易所创业板股票上市规则（2024年修订）》（以下简称"《股票上市规 则》"）、《上市公司独立董事管理办法》（以下简称"《独董管理办法》"）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作 （2023年12月修订）》的相关要求，结合公司实际情况，特制定本制度。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能妨碍其进行独立 客观判断关系的董事。 第三条 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人、 ...

Financial Performance - The company reported a decline in performance, with specific reasons detailed in the "Analysis of Four Main Businesses" section of the report[5]. - The company's operating revenue for 2024 was ¥5,829,800,576.60, a decrease of 14.94% compared to ¥6,853,359,543.02 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥317,075,752.08, representing a significant decline of 242.76% from ¥567,448,293.44 in 2023[21]. - The net cash flow from operating activities decreased by 40.19% to ¥122,341,832.53 in 2024, down from ¥204,544,610.05 in 2023[21]. - The company's basic earnings per share for 2024 was -¥0.7668, a decrease of 240.29% from ¥0.5466 in 2023[21]. - The company reported a total of ¥40,433,908.96 in non-recurring gains and losses for 2024, compared to ¥7,604,237.83 in 2023[28]. - The company experienced a negative net profit for all four quarters of 2024, with the fourth quarter showing a net loss of ¥265,404,923.97[24]. - The net profit attributable to the company, after deducting non-recurring gains and losses, was a loss of ¥493,091,896.83, a decline of 259.33% compared to the previous year[61]. - The comprehensive gross profit margin for the main business was 25.87%, down 5.57% year-on-year[61]. Strategic Outlook - The company plans to enhance its future development strategies as outlined in the "Outlook for Future Development" section[5]. - The company aims to become a leading global pharmaceutical equipment provider by around 2030, focusing on a comprehensive solution for pharmaceutical production 4.0[45]. - The company is enhancing its brand influence in international markets, with a steady increase in overseas market share[49]. - The company aims to leverage its technological advantages and international strategies to enhance competitiveness in the mid-to-high-end market[39]. - The company plans to further expand its international market presence by segmenting global markets into five major regions, improving local responsiveness[69]. Market Position and Industry Trends - The company is positioned as a leading enterprise in the pharmaceutical equipment industry, focusing on providing specialized and intelligent solutions[31]. - The global pharmaceutical equipment market is projected to exceed $50 billion in 2024 and $80 billion by 2030, with a CAGR of approximately 6-8%[32]. - China's pharmaceutical manufacturing market is expected to reach $191.7 billion in 2024, with a CAGR of about 7.5% from 2024 to 2032[37]. - The demand for personalized, small-batch, and multi-variety production is increasing, driving a shift towards modular and flexible equipment[34]. - The company is benefiting from the upgrade of the pharmaceutical industry and is transitioning towards high-end manufacturing, enhancing its international competitiveness[31]. Product Development and Innovation - The company has developed a digital water technology product chain, providing lifecycle services for pharmaceutical water, water treatment, wastewater treatment, and resource utilization, while also expanding applications to new energy, electronic semiconductors, and fine chemicals[50]. - The company has expanded its product offerings to include a comprehensive skincare and daily chemical solution, exemplified by the successful establishment of a smart beauty factory for Shangmei Co., integrating industrial automation, intelligent control, and information management[50]. - The company has successfully developed a series of specialized robots for clean and sterile environments, addressing the market's demand for high-precision and flexible production[55]. - The company has introduced advanced processing techniques for various materials, improving product durability and market competitiveness[51]. - The company has launched a new sterilization logistics system targeting vials, with a production speed of 3-4 packages per minute[90]. Financial Management and Investments - The company reported a fair value change of ¥3,903,335 in financial assets, with a total of ¥630,775,465 at the end of the period[104]. - The company issued 10 million convertible bonds with a total fundraising amount of ¥100,000,000, netting ¥98,681,460 after deducting issuance costs[112]. - The company has ongoing significant non-equity investments, but specific details were not disclosed[107]. - The company has committed to various investment projects with a total investment amount of RMB 98.6 million, with a progress rate of 98.2%[114]. - The company plans to use RMB 154.3252 million to replace self-raised funds that were previously invested in fundraising projects[115]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and regulations, and enhancing risk prevention capabilities[135]. - The board of directors operates in accordance with legal requirements, with a focus on diligent performance of duties and responsibilities[138]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[140]. - The company ensures timely and accurate information disclosure, adhering to relevant regulations and providing equal access to all investors[143]. - The internal control audit report issued a standard unqualified opinion, confirming the effectiveness of the financial reporting internal controls[200]. Human Resources and Employee Management - The total number of employees at the end of the reporting period was 7,005, including 4,012 at the parent company and 2,993 at major subsidiaries[184]. - The company has implemented a performance-oriented salary system, linking salary increases directly to performance assessments[186]. - The company has established a comprehensive talent development system, including training plans for new employees and ongoing professional development for existing staff[187]. - The company has reduced its R&D personnel by 29.67% from 2,720 in 2023 to 1,913 in 2024[93]. - The company has a total of 912.9 million shares of restricted stock that will be canceled due to performance assessment failures, affecting 559 incentive recipients[192].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,083,171,677.45, a decrease of 22.19% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥8,556,904.43, an improvement of 59.00% from a loss of ¥20,871,739.14 in the previous year[4]. - Basic and diluted earnings per share were both -¥0.0145, showing a 59.04% improvement from -¥0.0354 in the previous year[4]. - The company's net profit margin was impacted by a significant increase in financial expenses, which rose to ¥22,886,756.40 from ¥10,384,913.00, reflecting a 120% increase[20]. - The net profit for the current period is -13,440,239.56, an improvement from -20,716,801.32 in the previous period, representing a decrease in net loss of approximately 35%[21]. - The total comprehensive income for the current period is 29,363,025.88, compared to -50,418,878.54 in the previous period, indicating a significant recovery[21]. - The total operating profit for the current period is -24,633,247.88, an improvement from -26,895,103.40 in the previous period, showing a reduction in operating losses[21]. Cash Flow - The net cash flow from operating activities improved by 67.85%, amounting to a net outflow of ¥147,730,837.30, compared to a net outflow of ¥459,497,946.67 in the same period last year[4]. - Cash flow from operating activities shows a net outflow of -147,730,837.30, an improvement from -459,497,946.67 in the previous period[23]. - Cash flow from investing activities has a net outflow of -119,669,546.19, compared to -868,984,903.03 in the previous period, indicating reduced investment losses[23]. - Cash flow from financing activities shows a net inflow of 109,815,057.03, a decrease from 1,102,167,793.19 in the previous period, reflecting a reduction in financing activities[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,204,719,138.23, a decrease of 0.80% from the end of the previous year[4]. - Current liabilities totaled ¥7,182,337,198.32, down from ¥7,347,852,543.54, indicating a reduction of approximately 2.3%[19]. - The company's cash and cash equivalents decreased to ¥1,149,546,287.64 from ¥1,278,390,795.81, a decline of 10.1%[18]. - The cash and cash equivalents at the end of the period amount to 810,399,084.13, compared to 279,193,839.84 at the end of the previous period, showing an increase in liquidity[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 26,863[12]. - The largest shareholder, Changsha Chutian Investment Group, holds 38.07% of shares, totaling 224,706,614 shares[12]. - Hunan Caixin Jingxin Investment Partnership holds 2.68% of shares, totaling 15,816,000 shares[12]. - Liu Yan, an individual shareholder, holds 1.99% of shares, totaling 11,722,250 shares[12]. - The top 10 shareholders account for a significant portion of the company's equity, with the largest shareholder alone holding over 38%[12]. - The company has no preferred shareholders as indicated in the report[14]. - There are no changes in the number of restricted shares for key executives during the reporting period[15]. - The total number of restricted shares at the end of the period is 14,118,283 shares[15]. - The report indicates that key executives have locked shares that can be released gradually over their tenure[15]. - The company has not engaged in any share lending or borrowing activities during the reporting period[12]. Cost Management - Research and development expenses decreased by 34.14%, amounting to a reduction of ¥49,391,500 compared to the previous year[9]. - The company implemented cost reduction and efficiency enhancement measures, resulting in a 16.86% decrease in period expenses compared to the previous year[8]. Investment and Financing - Investment income increased by 424.89%, amounting to an increase of ¥1,430,200 compared to the previous year due to higher returns from bank wealth management products[9]. - The company reported a significant decrease in financing cash flow, down 90.04% to a net outflow of ¥99,235,270, primarily due to the absence of convertible bond issuance in the current period[10]. Revenue and Sales - The report indicates that sales revenue from goods and services was 1,404,767,950.05, down from 1,743,978,201.95 in the previous period, indicating a decline of approximately 19%[23]. - Total operating revenue for the current period was ¥1,083,171,677.45, a decrease of 22.2% compared to ¥1,392,029,678.89 in the previous period[20]. - Total operating costs amounted to ¥1,123,822,892.53, down 22.1% from ¥1,443,898,305.35 in the previous period[20]. Project Updates - The company has extended the timeline for the "Medical Equipment and Materials Technology Research Center Project" to March 2026, reflecting a cautious approach to current industry conditions[17]. - The board decided not to adjust the conversion price of the "Chutian Convertible Bonds" downward, maintaining the current terms for the next three months[16].

董秘： 您好！为保持2024年度报告与2025年一季度报告同步披露，故向深交所申请对年报披露时间进 行了调整，具体业绩情况届时请查阅相关报告。谢谢！ 当日关注点 交易信息汇总：4月24日主力资金净流出36.61万元，散户资金净流出63.22万元，而游资资金净流 入99.83万元。 交易信息汇总 董秘最新回复 投资者： 董秘您好，公司的产品对美国加征关税有没有影响，占比多少，今后是否加强欧洲布局 董秘： 您好！公司产品目前出口美国占总收入比非常小。公司将持续加大欧洲市场的拓展，进一步提 升在欧洲市场的占有率。以头部制药企业和高价值客户为主，对标国际头部制药装备同行，进一步提升 国际销售业务的利润水平。持续构建楚天科技在国际上的品牌影响力，持续深化国际销售及服务的本土 化策略，打造以高性价比、高效服务的品牌形象。谢谢！ 投资者： 贵公司年报怎么调整到29号了，是因为业绩太差了吗 截至2025年4月24日收盘，楚天科技(300358)报收于6.81元，下跌0.87%，换手率1.01%，成交量5.83万 手，成交额3993.21万元。 4月24日，楚天科技的资金流向情况如下：主力资金净流出36.61万元；游资资金净流 ...

Investment Rating - The report suggests a positive outlook for the pharmaceutical industry, indicating a potential for outperformance compared to the overall market [27]. Core Insights - The report highlights the impact of the recent U.S. tariff measures, which include a 34% additional tariff on Chinese goods, and the subsequent Chinese countermeasures that may benefit domestic pharmaceutical companies [3][4][5]. - It emphasizes the growth in China's pharmaceutical exports, particularly to the U.S., which reached $19.05 billion in 2024, marking an 11.7% increase year-on-year [6][7]. - The report identifies specific sectors within the pharmaceutical industry that may benefit from the tariff situation, including blood products, high-end raw materials, medical devices, and innovative drugs [18][19]. Summary by Sections Tariff Impact - The U.S. has implemented a 34% tariff on Chinese goods, which affects a wide range of medical supplies and devices, while China has responded with similar tariffs on U.S. imports [4][5]. - The tariffs are expected to disrupt the supply of imported blood products, potentially increasing demand for domestic alternatives [18]. Trade Statistics - In 2024, China's total pharmaceutical trade amounted to $199.376 billion, with exports at $107.964 billion and imports at $91.412 billion, showing a slight decline in imports but a recovery in exports [6][11]. - The U.S. remains the largest market for Chinese pharmaceutical exports, accounting for 17.6% of total exports [7][11]. Sector Opportunities - Blood Products: The tariff on U.S. imports may lead to increased domestic production and sales of blood products, with companies like Tian Tan Biological, Hualan Biological, and others positioned to benefit [18]. - High-End Raw Materials: The report suggests that domestic manufacturers of critical raw materials and consumables may gain market share due to reduced competition from U.S. imports [18]. - Medical Devices: Companies focusing on high-value medical devices are recommended for their potential to capture market share from imported products [18]. - Innovative Drugs: The report encourages investment in companies involved in the development of innovative drugs, particularly those that can replace U.S. imports in oncology and vaccine sectors [19].

4月2日，楚天科技今日收盘7.74元，上涨4.74%，最新市净率1.02，创14天以来新低，总市值45.69亿 元。 截至2024年三季报，共有32家机构持仓楚天科技，其中基金32家，合计持股数647.66万股，持股市值 0.44亿元。 楚天科技股份有限公司主营业务为制药装备的研发、设计、生产、销售和服务。主要产品为无菌制剂解 决方案及单机、检测包装解决方案及单机、生物工程解决方案及单机、固体制剂解决方案及单机、制药 用水装备及工程系统集成、EPC工程设计服务。公司已发展成为国内制药装备行业领军企业之一，同时 也成为了全球医药装备行业的知名企业之一。 最新一期业绩显示，2024年三季报，公司实现营业收入41.71亿元，同比-18.75%；净利润-187253063.9 元，同比-165.18%，销售毛利率25.94%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13楚天科技-29.0214.411.0245.69亿行业平均 46.8850.714.88109.12亿行业中值33.6731.142.5548.71亿1硕世生物-1962.70-1962.701.2340.55亿2诺唯 赞-584.37 ...